Drug intelligence / Profile preview

TREG-Derm-2

Development stage: Preclinical
Lead developer: TregTherapeutics
Modality: Vaccines & Immunotherapeutics

Overview

TREG-Derm-2 is a preclinical-stage tolerogenic immunotherapy being developed by TregTherapeutics for the treatment of dermatological autoimmune diseases. The therapeutic is based on the company's proprietary TILAC (Tolerance Induction via Linked Adjuvant/Cytokine conjugate) platform, which utilizes an alum-based adjuvant conjugated to an anti-inflammatory cytokine. This platform is designed to shift the dendritic cell microenvironment from immunogenic to tolerogenic signaling, promoting the expansion of regulatory T cells (Tregs) and retraining the immune system to restore immune tolerance without causing broad immunosuppression.

Beyond the preview

Go deeper on TREG-Derm-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TREG-Derm-2.

Explore the full profile